CTOs on the Move

Immunic

www.imux.com

 
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.imux.com
  • 1200 Avenue of the Americas Suite 200
    New York, NY USA 10036
  • Phone: 332.255.9811

Executives

Name Title Contact Details

Similar Companies

Aclario

Aclario is a Vienna, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NextGen Pharma Technologies

NextGen Pharma Technologies is a Colorado Springs, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).

Zerigo Health

Our Zerigo Health Solution is the newest advance in the treatment of psoriasis, vitiligo & eczema - available at-home for your convenience!

Embecta

Embecta will be the name of the independent, publicly-traded company that will hold BD`s Diabetes Care business